A Taiwanese man in his 50s woke up blind in one eye after using a GLP-1 weight-loss injection for about four months, the first such case to reach Taiwan's drug injury relief review. On November 9, the U.S. Food and Drug Administration warned that GLP-1 drugs may raise the risk of a rare optic nerve condition that can cause blindness and ordered label changes.
According to the United Daily News, the man has severe symptoms of chronic obstructive pulmonary disease (COPD) that left him short of breath when walking, and a body mass index of 32, classed as moderate obesity, which worsened his breathing. He paid out of pocket for Ozempic, a semaglutide-based GLP-1 drug, and used it for about four months, losing 10 kilograms without common side effects such as nausea or vomiting, while his breathing improved markedly.
광고 문의 · 300×250On the morning of February 27 this year, however, he woke to find he could not see out of his right eye and that his left eye was blurred. When he went to the emergency department of Taipei Veterans General Hospital, vision in his left eye had dropped to 0.1, and an 'eye stroke' was suspected. Public broadcaster PTS reported that neither eye had improved six months later. The diagnosis was non-arteritic anterior ischemic optic neuropathy (NAION), in which reduced blood flow to the front of the optic nerve causes sudden vision loss.
Su Yi-feng, a pulmonologist at Taipei City Hospital who had been treating him, suspected an adverse drug reaction, reported it to the Ministry of Health and Welfare and helped the patient apply for drug injury relief. Taiwan's Food and Drug Administration confirmed it is the first relief application in Taiwan over blindness after GLP-1 use. The Drug Relief Foundation received the case in late March, formally accepted it in late April and sent it to the review committee in late October; in November the agency asked the medical institution to explain why the drug was prescribed and at what dose.
A key issue is the approved use. According to the Taipei Times and the United Daily News, the drug is approved in Taiwan only for type 2 diabetes, so its use for weight loss is off-label. Lin Yi-chu of the agency's Medicinal Product Division said the review committee will decide eligibility based on specific facts such as the purpose of use and the prescribed amount. Su said adverse reactions cannot be predicted and that the government should not start by questioning frontline doctors and patients.
In a safety communication on November 9, the U.S. FDA said GLP-1 receptor agonists may increase the risk of NAION and required manufacturers to add the information to their labels. Taiwan's FDA said it had already required warnings on semaglutide products in June and is considering extending them to the whole GLP-1 class, as the United States has done. Since the drugs were approved in 2023, it has received 314 reports of suspected adverse reactions linked to GLP-1 drugs as of November 5, 12 of them involving the eyes, including this NAION case; most involved the digestive tract.
Experts stress that the risk is very rare. Su put the incidence at about one to 1.5 cases per 10,000 users. Ou Hung-yi, chair of the Taiwan Association of Diabetes Educators, said the warning deserves attention but that research findings are not yet consistent and causation is unclear, urging diabetes patients not to stop their medication on their own, which could disrupt blood sugar control. With weight-loss injections also growing in popularity in Korea, readers are advised to use them only with a prescription and to seek medical care immediately if their vision changes suddenly.